Clinical Trial Update: Monotherapy With Eribulin In Her2 Negative Metastatic Breast Cancer as a First Line Treatment [Phase 2]

View source ↗

Summary

Phase 2 trial of eribulin monotherapy as first-line treatment for HER2-negative metastatic breast cancer completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Eribulin (Halaven) (eribulin mesylate)

Snippet

Sponsor: MedSIR | Conditions: Breast Neoplasm, Metastasis | Phase 2 | Status: COMPLETED | Results posted: 2025-06-08